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Efficient hematopoietic recovery following trans-
plant requires a bone marrow microenvironment
capable of supporting diverse processes.
Transplanted stem and progenitor cells must home
to the marrow, adhere to endothelial cells, and sub-
sequently migrate to supportive hematopoietic
niches. Bone marrow microvascular endothelial
cells line the luminal surfaces of the marrow
microenvironment in a position to serve as gate-
keepers to the marrow microenvironment. They
have a key role in the regulation of hematopoietic
cell chemotaxis into and out of the marrow space.
This function is regulated by the complex interplay
of cellular adhesion molecules including vascular
endothelial cell adhesion molecule-1 (VCAM-1),
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Abstract
Chemotherapy alteration of the bone marrow microenvironment has the potential to influence hematopoietic recovery
following transplantation. To discern the effect of specific drugs on components of the complex marrow microenvi-
ronment, in vitro models have significant utility. In the current study we sought to determine whether dermal (HMEC-
1) and marrow derived endothelial cells (BMEC-1) respond differently to identical chemotherapy exposure. BMEC-1
cells were consistently more sensitive to etoposide exposure than HMEC-1 cells, measured as reduced viability.
BMEC-1 also had reduced focal adhesion kinase (FAK) and VCAM-1 protein expression following chemotherapy, in
contrast to dermal derived endothelial cells in which neither protein was influenced dramatically by etoposide. The
two endothelial cell lines had markedly different levels of baseline VE-Cadherin protein, which was modestly altered
by treatment. These data indicate that marrow derived endothelial cells have disruption of specific proteins following
chemotherapy that may influence their ability to facilitate hematopoietic cell entry or egress from the marrow. In addi-
tion, these observations suggest that while BMEC-1 and HMEC-1 share a variety of characteristics, they differ signif-
icantly in their response to stress and should be incorporated into specific models with this consideration.
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Introduction
endothelial cell associated selectin (E-Selectin),
vascular endothelial cell cadherin (VE-Cadherin),
and many others. 
Interactions between hematopoietic cells within
the marrow space and endothelial cells have also
been implicated in the control of hematopoietic dif-
ferentiation and management of the hematopoietic
progenitor compartment. Iatrogenic damage
incurred by this intricate system, in the setting of
dose intense chemotherapy or bone marrow trans-
plant conditioning regimens, could potentially lead
to dysregulated chemotaxis as well as hemato-
poiesis. In previous reports, radiation and chemo-
therapy induced damage of endothelial cells in the
lungs and liver has been implicated in the patho-
physiology of transplant complications [1-7]. 
Human umbilical vein endothelial cells
(HUVEC) have served as the major model for inves-
tigating endothelial pathophysiology. These cells are
relatively easy to derive and maintain for finite peri-
ods of time and as such, have broad utility.
However, there is evidence to suggest that HUVEC
may not be the most representative model to inves-
tigate all aspects of endothelial cell function. 
Marrow derived endothelial cells have been
shown to better support adhesion and migration of
hematopoietic cells than HUVEC or lung endothe-
lial cells [8,9]. Sulfation patterns of proteoglycans,
important in the presentation of chemokines such as
stromal cell derived factor-1 (SDF-1), have also
been found to differ between the two cell sources
[10,11]. HUVEC express high levels of Fas ligand
(CD95) which is not expressed by endothelial cells
from adult tissue sources [12]. Fas ligand induces
activation of several proinflammatory cytokines
which could influence cell adhesion, chemotaxis,
and response to stress as well as inducing apoptosis
in susceptible cells [13]. 
HUVEC also express higher levels of Steel fac-
tor and its receptor, Kit, compared to primary adult
aorta cells either constitutively or following stimu-
lation [14]. HUVEC expression of intracellular
adhesion molecule-1 (ICAM-1) and endothelial
linked adhesion molecule-1 (ELAM-1/E-Selectin)
were found to be reduced in comparison to adult
aortic endothelial cells in this study as well. Tan and
colleagues compared human saphenous vein
endothelial cells (HSVEC) with HUVEC and found
that HSVEC could upregulate CD80 via CD40 lig-
ation while HUVEC could not, that HSVEC do not
express CD54, and that HUVEC were more respon-
sive to stimulation by incitatory cytokines [15].
Together, these observations emphasize differences
between endothelial cells of varied origins. 
Much work has focused on irradiation induced
endothelial cell damage. Many investigators have
shown that irradiation results in alterations to
endothelial cells including increased expression of
adhesion molecules [16], cytokine production [17],
von Willebrand factor [17], and increased apoptosis
[18]. Gaugler, et al. have shown that irradiation of
a human bone marrow endothelial cell line resulted
in increased transmigration of CD-34+ cells [19]
with increased permeability accompanied by
increased ICAM-1, PECAM-1, and numerous
myeloid differentiating cytokines. Investigations
into the effects of chemotherapy agents on endothe-
lial cells have centered on complications of veno-
occlusive disease [1-3], and pulmonary fibrosis
[5,20] with less focus on marrow endothelial cells.
In this study we compared alterations in sur-
vival, adhesion molecule expression, and chemo-
taxis across two endothelial cell lines following
etoposide (VP-16) exposure. The human bone mar-
row endothelial cell line-1 (BMEC-1), derived from
human bone marrow, and the human microvascular
endothelial cell line-1 (HMEC-1) derived from
human foreskins differ in adhesion molecule
expression, survival, and ability to regulate chemo-
taxis following treatment. In addition, alterations in
focal adhesion kinase (FAK) and VE-Cadherin pro-
tein in response to Etoposide (VP-16) were shown
to be unique to the cell line evaluated. Collectively,
these data suggest functional distinctions between
the two cells lines that warrant careful considera-
tion when designing models to study bone marrow
alterations associated with chemotherapy exposure. 
Materials and methods
Cell lines
Growth factor independent transformed microvascular
endothelial cell lines were obtained from the CDC. The
dermal derived microvascular endothelial cell line,
HMEC-1, was initially derived by Dr. Thomas Lawley of
Emory University and Dr. Edwin Ades and Mr.
Francisco J Candal of the CDC [21,22]. The marrow
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derived microvascular endothelial cell line, BMEC-1,
was also a kind gift of Mr. Candal and Dr. Rafii [23].
Both cell lines were maintained and grown as previous-
ly described [21-23].
JM-1 cells were used to evaluate chemotaxis across
endothelial cell layers established on transwell mem-
branes. These factor independent cells were purchased
from the ATCC (ATCC#CRL-10423) and were grown
according to the recommendation of the depositor. They
have a pre-B cell acute lymphocytic leukemia (pre-B
ALL) phenotype, and are CXCR-4 and very late antigen-
4 (VLA-4) positive. 
Chemotherapeutic drugs
VP-16 was stored at -20°C at 20 mg/ml and was diluted
in the appropriate media immediately prior to use at con-
centrations of 50, 75, and 100 µM. These chemothera-
peutic drug doses were chosen to approximate doses
described in clinical settings of transplantation and high-
dose chemotherapy regimens [24].
Evaluation of endothelial cell viability
Confluent layers of BMEC-1 and HMEC-1 were pre-stim-
ulated with 10 ng/ml tumor necrosis factor-α (TNF-α) for
24 hours and then exposed to VP-16 at concentrations of
50, 75, and 100 µM. After an additional 24 hours, cells
were collected with Trypsin/ EDTA and analyzed by try-
pan-blue exclusion counting. The ratio of unstained cells
compared to the total number of cells per culture condition
was calculated as the percent survival. Adherent and non-
adherent cells for each condition were analyzed. Each
treatment group was evaluated in triplicate.
Assessment of apoptosis and flow cytometry
To evaluate apoptosis of endothelial cells following
chemotherapy exposure, cells were stained with fluores-
cein isothiocyanate (FITC)-conjugated annexin-V using
the TACS apoptosis detection kit (R & D systems,
Minneapolis, MN). Adherent cells, as well as any cells
that detached during treatment, were collected for evalu-
ation. Following annexin staining, samples were evaluat-
ed by flow cytometry and data analyzed using CellQuest
(Becton Dickinson, San Jose, CA). 
FACS Analysis of endothelial cell adhesion
molecule expression
Endothelial cell layers grown to confluency in tissue
culture plates were pre-stimulated with TNF-α
10ng/ml 24 hours prior to exposure to VP-16 100 µM
for 24 and 48 hrs. Cells receiving pre-stimulation only
and unstimulated cells served as controls. Endothelial
cells were then detached with Trypsin/EDTA and
washed in cold phosphate buffered saline (PBS). Cells
were then incubated for 30 minutes with 100ng/sample
of the following antibodies: mouse-anti-human VCAM-1
(CD106, Pharmingen, San Diego, CA), mouse- anti-
human-PECAM (CD-31), mouse-anti-human ICAM-1
(CD-54), mouse- anti-human-E-Selectin (CD-62E), P-
selectin (CD-62P) or L-Selectin, (CD-62L, R&D,
Minneapolis MN ), diluted in PBS/3%BSA. Samples
were subsequently washed with PBS/3%BSA/0.2%
Tween 20 before incubating with 100ng/sample goat-
anti-mouse IgG – RPE (Southern Biotechnology
Associates, Birmingham, Ala) for 30 minutes. After
additional washes with PBS/3% BSA/0.2% Tween 20,
cells were fixed in 1% paraformaldehyde, collected on a
FACScan (Becton Dickinson, San Diego, CA), and ana-
lyzed by CellQuest software (Becton Dickinson, San
Diego, CA). Matched isotype control samples were
stained in all experiments to evaluate nonspecific back-
ground fluorescence.
Chemotaxis Assays
HMEC-1 and BMEC-1 were grown to confluency in
100 mm dishes then transferred to Transwell inserts (5
µm pore size, Costar, Wiesbaden, Germany). The
endothelial layers were pre-stimulated with TNF-α in
the lower as well as upper chambers of the transwell for
24 hours to insure treatment of both sides of the
endothelial layers. The membranes were then washed
and moved to new chambers where they were exposed
to 100 µM VP-16 for 24 hrs. Identically treated mem-
branes were stained with Accustain (Wright stain, mod-
ified, Sigma, St. Louis, MO) to visually confirm main-
tenance of the endothelial layers on the transwell filter.
After an additional gentle PBS rinse, the transwells were
placed in chambers containing 350 µl media with or
without 100 ng/ml SDF-1 in the lower chamber, and
150,000 JM-1 cells in 150 µl media in the upper cham-
ber. After 4 hours, the media in the lower chamber was
collected and the number of JM-1 cells that migrated
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was enumerated. Unstimulated endothelial cell layers
and stimulated, untreated cell layers served as controls.
In addition, chemotaxis of JM-1 cells across transwells
without endothelial cell layers was evaluated, with or
without SDF-1 in the lower chamber, to measure spon-
taneous migration as well as chemotaxis toward SDF-1
without any barrier. All treatment groups were evaluat-
ed in triplicate.
Western Blot Analysis of FAK and VE-
Cadherin
Confluent layers of endothelial cells were prestimulated
with TNF-α for 24 hours then treated with 100 µM VP-
16. Unstimulated cell layers and TNF-α prestimulated
cells that were not exposed to chemotherapy served as
controls. BMEC-1 or HMEC-1 cell pellets were lysed in
CCLB buffer (50 mM Tris-HCl, pH 7.4, 150 mM NaCl,
1% TritonX-100, 0.25% Na-deoxycholate, 0.5% SDS, 1
mM EDTA, 1 mM NaF, 1mM DTT, 1 mM PMSF, 1 mM
activated Na3VO4, aprotinin, leupeptin, pepstatin) on
ice for 15 minutes. Following centrifugation at 14,000
rpm for 15 minutes, supernatants were harvested and
stored at -20 °C until use. Protein concentrations were
determined using the BCA protein assay (Pierce,
Rockford, IL). Protein samples were resolved on SDS-
PAGE gels and electrotransferred to nitrocellulose
membranes. Membranes were blocked in TBS/5% non-
fat dry milk/0.05% Tween-20 at room temperature for 1
hour and probed with antibodies specific for human VE-
Cadherin (Santa Cruz Biotechnology, Santa Cruz, CA) ,
or human FAK (BD Pharmingen, San Diego, CA).
Isotype matched control antibodies were used to evalu-
ate nonspecific binding. Following washes in TBS/0.1%
Tween-20/3% milk, membranes were incubated with
horseradish peroxidase labeled goat-anti-mouse IgG,
and signal detected with Luminol. Signal for each pro-
tein of interest was normalized to GAPDH probed on
the same blot.
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Fig. 1 VCAM-1 alterations following VP-16 exposure differ between BMEC-1 and HMEC-1. BMEC-1
VCAM-1 expression was decreased following VP-16 exposure while HMEC-1 VCAM-1 expression was unchanged.
BMEC-1 expressed E-Selectin following TNF-α exposure, while HMEC-1 did not.
Results
VCAM-1 alterations following VP-16
exposure differ between BMEC-1 and
HMEC-1
To investigate changes in adhesion molecule
expression by BMEC-1 and HMEC-1 following
VP-16 exposure, cell layers were treated with VP-
16 and analyzed by FACS as described in the
materials and methods. Both cell lines expressed
VCAM-1 following TNF-α stimulation as had
been reported in the initial descriptions of these
cell lines [22,23]. Alterations in VCAM-1 surface
expression were detected following treatment
with 100 µM VP-16 in BMEC-1 only (Fig. 1).
VCAM-1 expression on HMEC-1 cells was not
diminished under identical conditions (Fig. 1)
As previously reported [21,23], both endothe-
lial cell lines constitutively expressed PECAM
and ICAM (data not shown). P-Selectin and L-
Selectin were not detected by FACS analysis
(data not shown). BMEC-1 cells expressed E-
Selectin following TNF-α exposure, while
342
Fig. 2 BMEC-1 viability is reduced following exposure to VP-16. (a) Trypan blue exclusion of BMEC-1 (grey tri-
angle) and HMEC-1 (black circle) following exposure to VP-16 at 50, 75, and 100 µM. (b) Annexin-V-FITC stain-
ing of BMEC-1 following exposure to VP-16.
HMEC-1 did not demonstrate TNF-α induced
expression of this protein (Fig. 1). Surface
expression of PECAM, ICAM, or E-Selectin, did
not change in response to VP-16 treatment (data
not shown).
BMEC-1 viability is reduced by VP-16
exposure more than HMEC-1
BMEC-1 were more sensitive to equal doses of
VP-16 when compared to HMEC-1 by trypan blue
staining (Fig. 2, A). Following exposure to 100 µM
VP-16, the highest dose evaluated, mean survival
of BMEC-1 cells was 65% (standard error (SE)
6.3%) as compared to mean HMEC-1 viability
which remained at 78% (SE 1.7%). This difference
was also observed following exposure to 75 µM
VP-16 with a mean survival of BMEC-1 cells of
65% (SE 2.9%) and mean survival of HMEC-1
cells of 82% (SE 3.5%). Annexin-V-FITC staining
of VP-16 treated BMEC-1 cells indicated that
VP-16 induced cell death was apoptotic in nature,
and did not differ significantly across the dosages
tested (Fig. 2, B).
Hematopoietic cell chemotaxis is increased
by VP-16 treatment of endothelial cell
layers
To elucidate potential alterations in endothelial cell
function following exposure to VP-16, chemotaxis
assays were completed as described in the materials
and methods section. Both marrow and dermal
derived cell layers diminished chemotaxis across
transwell membrane when compared to control
wells without endothelial cell layers (Fig. 3).
Exposure of endothelial cell layers to VP-16 result-
ed in increased spontaneous JM-1 cell migration
across the endothelial layers, as well as JM-1
chemotaxis toward recombinant SDF-1 in the bot-
tom chamber. Migration of JM-1 cells across VP-16
treated BMEC-1 was increased to a greater extent
than across HMEC-1 treated identically.
Alterations in FAK and VE-Cadherin
To further investigate potential mechanisms for the
alterations in chemotaxis patterns across BMEC-1
and HMEC-1 described above, Western blot analy-
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Fig. 3 JM-1 cell migration is
increased following VP-16 treat-
ment. The control group represents
JM-1 migration across transwell
membranes toward media alone
(vertical bars) or 100 g/ml SDF-
1(black bar). BMEC-1 or HMEC-1
represent JM-1 migration across the
specific endothelial cell type indi-
cated. Pretreatment of endothelial
cells with VP-16 and chemotactic
stimulus in the bottom well is indi-
cated in the figure key.
sis of FAK and VE-Cadherin were completed.
Expression of either protein was normalized to
GAPDH probed on the same membrane to control
for lane loading error. VE-Cadherin protein was
detected in both cell lines at baseline; however,
BMEC-1 had higher baseline levels of VE-
Cadherin than HMEC-1 (densitometry readings
normalized to GAPDH of 4.8 and 0.4 respectively).
Densitometric analysis indicated only modest
changes in VE-Cadherin following exposure of
TNF-α prestimulated cell lines to VP-16 (Fig. 4).
FAK was present at baseline in relatively equal
amounts in both cell lines. Densitometric analysis
indicated a reduction in TNF-α prestimulated
BMEC-1 FAK levels following VP-16 exposure
(densitometry readings normalized to GAPDH and
control of 1.3 reduced to 1.1), while no change was
detected in FAK levels of VP-16 treated HMEC-1
(Fig. 4).
Discussion
The success of bone marrow transplantation
depends, in part, on the ability of transplanted
hematopoietic progenitors to migrate into the host’s
marrow cavities and establish interactions with sup-
porting cells of the microenvironment. Endothelial
cells play a critical role in hematopoietic reconstitu-
tion by serving as the barrier between the blood
spaces and marrow microenvironment. Transplan-
ted stem or progenitor cells must efficiently interact
with bone marrow endothelial cells prior to further
migration into marrow niches that support
hematopoietic survival and further development.
Chemotherapy damage of these microvascular
endothelial cells may disrupt the efficiency of this
early, and essential, step in recovery. 
In the current study we show that survival of
BMEC-1 was decreased to a greater extent follow-
ing VP-16 exposure than HMEC-1 (Fig. 2, A).
Annexin-V-FITC staining of HMEC-1 indicated
initiation of apoptosis in response to VP-16 expo-
sure (Fig. 2, B). Differences in cell line sensitivity
to stressors, such as exposure to chemotherapeutic
agents, could potentially bias interpretation of
results if not carefully considered. Comparison of
several different endothelial cell lines, derived from
different anatomic locations, may enable investiga-
tors to understand the mechanisms behind these dif-
ferences and how they may influence pathophysiol-
ogy in their specific original anatomic locations.
Alterations in VCAM-1 expression following
VP-16 exposure were also found in this study (Fig.
1). VLA-4 binding to VCAM-1 is required for pro-
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Fig. 4 Alterations in VE-cadherin and FAK following VP-16 exposure. Western analysis for VE-cadherin or FAK
was carried out on BMEC-1 or HMEC-1 following prestimulation with TNF-α as indicated below the columns.
Unstimulated cells were used as controls.
genitor cell attachment to endothelial cells and sub-
sequent binding to stromal cells within the marrow
parenchyma [24-27]. Unlike other ligand interac-
tions, VLA-4 activation is required for functional
binding to VCAM-1. This has been shown for
VLA-4 interaction with VCAM-1 on endothelial
cells, an essential initiating event in hematopoietic
cell immigration into marrow spaces. Antibodies
directed against VCAM-1 or VLA-4 have been pre-
viously shown to inhibit stem cell homing [28-30].
Treatment of human umbilical cord endothelial
cells with etoposide has been shown to down-regu-
late VCAM-1 expression [28], indicating that mod-
ulation of adhesion molecule expression is one
means by which chemotherapy may alter endothe-
lial cell characteristics. Consistent with these
reports, both BMEC-1 and HMEC-1 were found to
have decreased expression of VCAM-1 following
exposure to VP-16. VCAM-1 binding to activated
VLA-4 also facilitates the majority of selectin-inde-
pendent interactions at this site [29]. Consistent
with the proposed importance of the role for
VCAM-1 in stem cell homing, engraftment of
SCID mice following transplantation of hematopoi-
etic progenitor cells has been shown to be depen-
dent on expression of VLA-4 and VLA-5 [33-35].
As such, these molecules are logical targets of
investigation in attempts to better understand mech-
anisms that underlie disrupted hematopoiesis fol-
lowing aggressive chemotherapy treatment.
Differential sensitivity and VCAM-1 expression
responses exhibited by endothelial cell lines should
be considered.
Initial interactions between transplanted hema-
topoietic cells and the microvascular endothelium
involve engagement of selectins. Both E- and P-
selectin are expressed constitutively on marrow
endothelial cells. E-selectin has been shown to play
a major role in initial binding of hematopoietic pro-
genitor cells to marrow endothelium in an in vitro
human bone marrow endothelial cell line model
using the transformed line HBMEC [30].
Attachment of normal mobilized peripheral blood
progenitors was blocked by anti-E-selectin anti-
body in this model. CD34+ cells also express lig-
ands for P-selectin. In a NOD/SCID mouse model,
mice lacking both P- and E-selectin expression
were found to have a 90 percent reduction in hom-
ing of transplanted human CD34+ cells by intravi-
tal microscopy [31]. E-Selectin expressed on bone
marrow endothelial cells has also been shown to
play a potential role in the regulation of
hematopoiesis through inhibition of proliferation of
CD-34+ cells and induction of apoptosis in a subset
of hematopoietic cells [32]. 
In the present study, and consistent with previ-
ous reports, BMEC-1 were found to express E-
selectin following TNF-α stimulation by FACS
analysis, while HMEC-1 did not express E-selectin
(Fig. 1). BMEC-1 E-selectin expression was not
altered following exposure to VP-16. This differ-
ence may contribute to the increased migration of
JM-1 cells across BMEC-1 compared to HMEC-1
observed in this study. It also highlights the poten-
tial utility of using these two cell lines to further
expand our understanding of the roles of E-selectin
in hematopoiesis.
To further investigate potential factors that may
contribute to the differences observed between
BMEC-1 and HMEC-1 as regulators of JM-1 cell
chemotaxis, western analysis of VE-Cadherin and
FAK was completed (Fig. 4). VE-Cadherin is a
transmembrane protein that is crucial to cell-cell
adhesion between endothelial cells. Earlier reports
indicate that antibody blocking of VE-Cadherin led
to increased neutrophil extravasation in a mouse
peritonitis model suggesting a role for this protein
in regulating permeability of vascular endothelial
cell layers [33]. In the current study, the VE-
Cadherin level was modestly decreased in BMEC-1
following VP-16 exposure (Fig. 4), coincident with
increased JM-1 cell chemotaxis toward SDF-1, as
well as random migration across BMEC-1 cell lay-
ers (Fig. 3). Chemotaxis of JM-1 cells across VP-16
treated HMEC-1 was also increased compared to
untreated control HMEC-1 layers but not to the
same degree as that observed with BMEC-1. These
observations suggest that altered VE-Cadherin may
be one factor that contributes to increased perme-
ability of bone marrow derived endothelial cells
following VP-16 exposure. Theoretically, chemo-
therapy induced alterations of endothelial cell junc-
tion integrity may influence both the “ease” with
which transplanted progenitor cells enter the mar-
row spaces, and may also affect the efficiency with
which specific chemotherapeutic agents mobilize
hematopoietic stem and progenitor cells. 
Recent work has linked VCAM-1 engagement
with decreased expression of VE-Cadherin on the
surface of a human marrow derived endothelial cell
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line independent of the cell line used in this report
[34]. This process was found to be mediated by pro-
duction of reactive oxygen species and led to
accompanying reorganization of the cytoskeleton,
widening of endothelial cell-cell gaps, and
increased migration of CXCR4+ cells across
endothelial layers towards an SDF-1 gradient.
However, in the current study, BMEC-1 demon-
strated a greater decrease in VCAM-1 expression
following exposure to VP-16, while also demon-
strating a greater promotion of chemotaxis. This
suggests either a decreased role of VLA-4: VCAM-
1 engagement in promoting intracellular gaps or
alternative means of activation of this pathway in
our model. 
Focal adhesion kinase (FAK) is a major tyrosine
kinase involved in signaling pathways downstream
of focal adhesions [35]. Focal adhesions consist of
integrins and the associated intracellular proteins
linking them to the cytoskeleton. Interactions with
cytoskeletal proteins in turn lead to changes in cell
shape, mobility, and permeability of cell layers.
Activation of FAK along with related adhesion
focal tyrosine kinase (RAFTK/Pyk2) by vascular
endothelial cell growth factor (VEGF) has been
shown to result in accelerated construction of focal
adhesions in neural microvascular endothelial cells
[36,37]. Blocking of this pathway led to loss of
focal adhesions, decreased spreading of the
endothelial cells, and decreased endothelial cell
migration [36,37]. In this study we report that expo-
sure to VP-16 lead to modestly decreased levels of
FAK in BMEC-1 alone. This difference may influ-
ence increased permeability of BMEC-1 layers,
measured as increased JM-1 spontaneous migration
or SDF-1 driven chemotaxis, compared to HMEC-
1 layers following exposure to VP-16.
Taken together, differences between HMEC-1
and BMEC-1 following VP-16 exposure evaluated
as viability, regulation of JM-1 cell chemotaxis, and
VCAM-1, VE-Cadherin, and FAK protein expres-
sion demonstrate the need to consider the source of
endothelial cells used in establishing in vitro mod-
els of the bone marrow microenvironment.
Investigation of the mechanisms underlying the dif-
ferences observed in this study may increase our
understanding of the regulation of chemotaxis in
the specific context of the bone marrow. Ultimately,
a better understanding of chemotherapy induced
changes in marrow endothelial cells may lead to
improvements in bone marrow transplantation pro-
cedures including optimized conditioning regi-
mens, supportive care to prevent endothelial cell
related complications, and improvements in
engraftment and patient outcomes.
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